

(PF1246) SECONDARY PERIPHERAL T-CELL LYMPHOMA IN A PATIENT OF DLBCL HARBORING CANCER SUSCEPTIBILITY GENE MUTATION FOLLOWING CD19/CD22 BISPECIFIC CAR-T CELL THERAPY

Topic: 26. Gene therapy, cellular immunotherapy and vaccination - Clinical

Xindi Liu¹, Qinlong Zheng², Liang Wang^{*1}

¹Beijing Tongren Hospital, Capital Medical University, Beijing, China; ²Beijing Gaobo Boren Hospital, Beijing, China;

Background

Chimeric antigen receptor (CAR)-T cell therapy has revolutionized treatment for relapsed/refractory B-cell malignancies, but rare secondary T-cell malignancies have emerged as a serious safety concern.

Aims

We report a case of secondary peripheral T-cell lymphoma (PTCL) definitively proven to originate from infused CD19/CD22 bispecific CAR-T cells, with comprehensive molecular characterization of oncogenic mechanisms.

Methods

A 66-year-old woman with diffuse large B-cell lymphoma (DLBCL) and history of breast and cervical cancers received autologous CD19/CD22 CAR-T cells in November 2024 following CNS relapse. Nine months post-infusion, she developed a lower lip mass diagnosed as PTCL, not otherwise specified (PTCL-NOS). Comparative genomic analysis of the CAR-T product and PTCL tissue was performed. Whole genome sequencing (WGS), T-cell receptor (TCR) clonality assessment, single-cell RNA sequencing (scRNA-seq), and targeted mutation analysis were conducted on pre-infusion CAR-T product, peripheral blood mononuclear cells (PBMCs), and PTCL tissue.

Results

TCR sequencing identified identical clonal rearrangements (*TRBD101/TRBJ2701* and *TRGV801/TRGJ101*) in both CAR-T product and PTCL, confirming clonal origin. WGS revealed pathogenic somatic mutations in *TET2* (*p.R1261H*, *p.E1755*) with higher variant allele frequencies in PTCL versus CAR-T product, indicating pre-existing mutations with subsequent clonal expansion. The patient harbored a germline *BLM* p.L107Ffs*36 mutation, contributing to genomic instability. Additional oncogenic events included del(11)(q23.2q25) involving *KMT2A* and *ATM*, loss of chromosome X, and clonal CAR vector integrations within tumor suppressor genes (*NF1*, *CBX5*, *RNF213*). scRNA-seq and flow cytometry of the CAR-T product showed no malignant population at infusion, excluding pre-existing malignancy.


Summary/Conclusion

This case provides unequivocal molecular evidence of CAR-T cell malignant transformation driven by three convergent factors: (1) pre-existing *TET2* driver mutations representing clonal hematopoiesis, (2) germline *BLM* deficiency exacerbating genomic instability, and (3) insertional mutagenesis from CAR vector integration. These findings underscore the critical importance of pre-infusion genomic screening of CAR-T products for CHIP-related mutations, cancer susceptibility gene testing in patients with prior malignancies, and lifelong surveillance for secondary malignancies in CAR-T recipients.

Copyright Information: (Online) ISSN: 2572-9241

©2026 The Author(s). HemaSphere is published by John Wiley & Sons Ltd on behalf of European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. **Abstract Book Citations:** Authors, Title, HemaSphere, 2026;10;(S1):pages. The abstract book DOIs can be found on the "Author Information" page.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.



Copyright Information: (Online) ISSN: 2572-9241
©2026 The Author(s). HemaSphere is published by John Wiley & Sons Ltd on behalf of European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
Abstract Book Citations: Authors, Title, HemaSphere, 2026;10;(S1):pages. The abstract book DOIs can be found on the “Author Information” page.
Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.